Caldan Therapeutics

Caldan, a spin-out company from the Universities of Glasgow and Southern Denmark, is developingnovel therapeutics targeting free fatty acid receptors for NASH, Type 2 Diabetes (T2D) and other potential indications. Caldan has arisen from a long-term collaboration between Professor Trond Ulven at the University of Southern Denmark and Professor Graeme Milligan of the University of Glasgow.
Social Link - Twitter: https://twitter.com/caldanthera
Social Link - Linkedin: http://www. linkedin.com/company /caldan-therapeutics
Employee Count: 7
Keywords: biotechnology research